Breakthrough in Cancer Treatment: European Approval for Sugemalimab
A groundbreaking advancement has been made in the field of cancer treatment with the recent approval by the European Commission of sugemalimab (branded as Cejemly®). This approval heralds a new era in the fight against non-small cell lung cancer (NSCLC), positioning sugemalimab